These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 30796190

  • 1. Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.
    Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD.
    Proc Natl Acad Sci U S A; 2019 Mar 12; 116(11):5160-5169. PubMed ID: 30796190
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.
    Shaffer CL, Dutra JK, Tseng WC, Weber ML, Bogart LJ, Hales K, Pang J, Volfson D, Am Ende CW, Green ME, Buhl DL.
    Neuropharmacology; 2019 Jul 15; 153():73-81. PubMed ID: 31015046
    [Abstract] [Full Text] [Related]

  • 3. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
    Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris PJ, Stewart BW, Thomas CJ, Thompson SM, Moaddel R, Gould TD.
    Br J Pharmacol; 2019 Jul 15; 176(14):2573-2592. PubMed ID: 30941749
    [Abstract] [Full Text] [Related]

  • 4. (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.
    Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA, Gould TD.
    Proc Natl Acad Sci U S A; 2019 Mar 26; 116(13):6441-6450. PubMed ID: 30867285
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice.
    Yamagishi A, Ikekubo Y, Mishina M, Ikeda K, Ide S.
    J Pharmacol Sci; 2024 Mar 26; 154(3):203-208. PubMed ID: 38395521
    [Abstract] [Full Text] [Related]

  • 9. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
    Yokoyama R, Higuchi M, Tanabe W, Tsukada S, Naito M, Yamaguchi T, Chen L, Kasai A, Seiriki K, Nakazawa T, Nakagawa S, Hashimoto K, Hashimoto H, Ago Y.
    Pharmacol Biochem Behav; 2020 Apr 26; 191():172876. PubMed ID: 32088360
    [Abstract] [Full Text] [Related]

  • 10. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
    Chou D, Peng HY, Lin TB, Lai CY, Hsieh MC, Wen YC, Lee AS, Wang HH, Yang PS, Chen GD, Ho YC.
    Neuropharmacology; 2018 Sep 01; 139():1-12. PubMed ID: 29953886
    [Abstract] [Full Text] [Related]

  • 11. Antidepressant actions of ketamine engage cell-specific translation via eIF4E.
    Aguilar-Valles A, De Gregorio D, Matta-Camacho E, Eslamizade MJ, Khlaifia A, Skaleka A, Lopez-Canul M, Torres-Berrio A, Bermudez S, Rurak GM, Simard S, Salmaso N, Gobbi G, Lacaille JC, Sonenberg N.
    Nature; 2021 Feb 01; 590(7845):315-319. PubMed ID: 33328636
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prelimbic cortex miR-34a contributes to (2R,6R)-hydroxynorketamine-mediated antidepressant-relevant actions.
    Ye L, Xiao X, Xu Y, Zheng C, Chen S, Luo T, Li Z, Du Y, Yuan Y, Li L, Liu B, Qin W, Chou D.
    Neuropharmacology; 2022 May 01; 208():108984. PubMed ID: 35131296
    [Abstract] [Full Text] [Related]

  • 16. NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine.
    Zanos P, Brown KA, Georgiou P, Yuan P, Zarate CA, Thompson SM, Gould TD.
    J Neurosci; 2023 Feb 08; 43(6):1038-1050. PubMed ID: 36596696
    [Abstract] [Full Text] [Related]

  • 17. Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission.
    Ye L, Ko CY, Huang Y, Zheng C, Zheng Y, Chou D.
    Neuropharmacology; 2019 Oct 08; 157():107667. PubMed ID: 31207251
    [Abstract] [Full Text] [Related]

  • 18. Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.
    Zhang K, Fujita Y, Hashimoto K.
    Sci Rep; 2018 Mar 05; 8(1):4007. PubMed ID: 29507385
    [Abstract] [Full Text] [Related]

  • 19. Sex-dependent metabolism of ketamine and (2R,6R)-hydroxynorketamine in mice and humans.
    Highland JN, Farmer CA, Zanos P, Lovett J, Zarate CA, Moaddel R, Gould TD.
    J Psychopharmacol; 2022 Feb 05; 36(2):170-182. PubMed ID: 34971525
    [Abstract] [Full Text] [Related]

  • 20. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.
    Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, Zarate CA, Thomas CJ, Moaddel R, Gould TD.
    J Psychopharmacol; 2019 Jan 05; 33(1):12-24. PubMed ID: 30488740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.